

Authors

Emma Davies (Corresponding author)
PhD Research Fellow, College of Human and Health Sciences, Swansea University,
Singleton Park, Sketty Lane, Swansea, Wales, UK, SA2 8PP
Tel: 07881535207 email: 878970@swansea.ac.uk

Dr Bernadette Sewell
Swansea Centre for Health Economics, Swansea, Wales, UK

Dr Mari Jones
Swansea Centre for Health Economics, Swansea, Wales, UK

Professor Ceri Phillips
College of Human and Health Sciences, Swansea, Wales, UK

Dr Jaynie Rance
College of Human and Health Sciences, Swansea, Wales, UK

Keywords

Opioid Analgesics; drug prescribing; socioeconomic status; trends; pain management

Word count

Main paper: 4115

Strengths and Limitations: 100

Abstract: 295

Additional statements: 222

Examining the burden of opioid prescribing for non-cancer pain considering socio-economic differences, in Wales. A retrospective database study examining trends between 2005 – 2015

Abstract

Objectives

To use a proxy-measure of oral morphine equivalent dose (OMED) to determine trends in opioid burden in people with non-cancer pain and explore differences related to deprivation status.

Design, setting and participants

Retrospective cohort study using cross-sectional and longitudinal trend analyses of opioid prescribing data from 78% of Welsh Primary Care General Practices, whose data is shared with the Secure Anonymised Information Linkage (SAIL) databank. Anonymised data for the period 2005 to 2015, for people aged 18 or over, without a recorded cancer diagnosis and who received at least one prescription for an opioid medicine was included.

Primary and Secondary outcomes

A proxy-measure of oral morphine equivalence dose (OMED) was used to describe trends in opioid burden over the study period. OMED burden was stratified by 8 drug groups and deprivation, based on the quintile measures of the Welsh Index of Multiple Deprivation 2011 (WIMD2011).

Results

In the 11 years examined, 22 641 424 prescriptions for opioids were issued from 345 primary care general practices in Wales. Daily OMED per 1000 population increased by 94.7% (from 16 266 mg to 31 665 mg). Twenty-eight percent of opioid prescribing occurred in the most deprived quintile. More than 100 000 000mg more OMED was prescribed in the most deprived areas of Wales, compared to the least deprived. Codeine prescribing accounted for 35% of the OMED burden in Wales over the study period.

Conclusions

Whilst opioid prescription numbers increased 44% between 2005 and 2015, the OMED burden nearly doubled, with a disproportionate OMED load in the most deprived communities in Wales. Using OMED provides an insightful representation of opioid burden, more so than prescription numbers alone. Socio-economic

differences are likely to affect pain presentation, access to support services and increase the likelihood of receiving an opioid prescription.

Strengths and limitations of this study

- This study forms part of the first large-scale examination of opioid prescribing in Wales and is the first to use oral morphine equivalent dose as an outcome measure.
- Access to anonymously linked data allows more detailed examination of demographic influences on opioid prescribing.
- The study used a proxy-measure for oral morphine equivalent dose due to unavailability of anonymously linked prescription dispensing data.
- Disproportionate levels of prescribing in particular populations have been reported in many countries; further research should seek to understand the reasons for the differences and develop means to address any inequality noted.

Introduction

The number of prescriptions for opioid medicines issued in the United Kingdom (UK) has increased substantially over the last twenty years (1-6). In particular, prescriptions for 'strong' opioids, such as morphine, oxycodone and fentanyl, have seen a higher increase than those classed as 'weak', like codeine and dihydrocodeine (1,2,6). Increases in prescribing persist, even when evidence to support using these medicines for people living with pain that is not acute, cancer or end-of-life related, is largely missing(7-11).

National and international concerns have focussed on the rising use of strong opioids (12-14). However, dose and duration of use are more likely indicators of harm or potential for dependence than the drug type (11, 15-20). The literature suggests adverse events occurred in 78% of cases for opioid use over extended periods of time (11,21,22). Similarly, increasing doses (8,15,23-25) have been associated with depression and anxiety (16,26,27) and an increased risk of dependence and misuse (20,28-30).

This is a particular concern in areas of high socioeconomic deprivation, where prescribing of potentially dependence forming medicines, including opioids, has been found to be more prevalent, especially for chronic, non-cancer pain in the UK (2,4,6,19,31-34) and internationally (35). Deprivation is a predictor for poor health outcomes and higher incidence of mental health disorders (36), and concomitant use of other medicines, such as benzodiazepine and anti-depressants, and opioids confer additional risk of harm to the user (19,34,37).

Wales has historically high levels of deprivation (38). In 2018, 23% of the Welsh population lived in poverty, which is more than in England, Scotland or Northern Ireland (39). Swansea, Rhondda Cynon Taff and Neath Port Talbot, some of the most deprived areas in Wales (40), have the highest opioid-related death rates in England and Wales (41) and higher numbers of non-fatal opioid overdoses were reported in Wales compared to England (42). However, a comprehensive analysis of Wales-wide opioid prescribing has only recently been undertaken (4).

The aim of this study was to examine the changes in opioid prescribing in Wales between 2005 and 2015. A proxy-measure of oral morphine equivalent dose (OMED) was used to standardise data and allow comparisons of the opioid burden from each drug in use. Data was stratified by deprivation quintile, to determine if opioid burden varies depending on socio-economic differences.

Method

This research was approved by the Information Governance Review Panel (IGRP) of the Secure Anonymised Information Linkage databank (SAIL), based in Swansea University (SAIL identification number: 0507).

Data source

The study used anonymised data held in the Secure Anonymised Information Linkage(SAIL) system, which is part of the national e-health records research infrastructure for Wales (43,44).

The main data source was the Primary Care General Practice (PCGP) dataset, which contained complete data from 1 January 2005 until 31 December 2015. A new

dataset was formed using one line per opioid prescription, linked to individual patient demographic data using unique Anonymised Linkage Fields (ALFs). The ALF allows cross-linking between different existing datasets, providing a record of all healthcare interactions for any individual whose data is available to SAIL. Primary Care General Practice data was linked to the Welsh Index of Multiple Deprivation 2011 (WIMD2011), based on the Local Super Output Areas (LSOAs) listed on the PCGP records.

Opioid prescriptions

Prescriptions are automatically assigned read codes at issue as a consistent means to identify data of interest (1,3,43,44). Read codes are a thesaurus of clinical terms used to record all interactions, diagnoses and interventions in Primary Care settings in Wales. A list of read codes was compiled for all prescribable oral and transdermal opioid medicines used for analgesia, including combination products, e.g. paracetamol and codeine (co-codamol), using the NHS Information Authority's Clinical Terminology Browser and accessed via the SAIL secure gateway. Products licensed for the management of misuse and injectable opioids, which are reserved for palliative care, were excluded.

Only data for people aged 18 years or older between 2005 and 2015 without a recorded cancer diagnosis (identified using read codes for cancer diagnoses or treatment) at any time between 2004 and 2015 were included in the analysis.

All data were subjected to repeated cross-sectional sampling to determine prescribing trends over the study period.

Oral morphine equivalent dose

Oral morphine equivalent dose (OMED) is normally calculated by multiplying the dose for each prescription (or a combination of doses, e.g. 10mg + 30mg tablets to give a total of 40mg per dose), by the equi-analgesic ratio of the opioid in question (1). The number of days' supply provided by each prescription is then divided by the numerical daily dose (NDD) taken from the free text on the prescription (e.g. 'one tablet to be taken twice daily'). This way, an OMED can be calculated per prescription or per individual over longer time periods (e.g. annual OMED) (1,2).

However, at the time of this study, dispensing data (42) could not be anonymously linked into SAIL datasets. Whilst the prescribed product, including strength, was recorded, details such as directions or quantity prescribed was unavailable to calculate the prescribed oral morphine equivalent dose (OMED) for each individual.

Therefore, each opioid product was allocated its OMED value based on conversion tables available for clinical practice (8,43) and dose and then multiplied by the recommended dose per day, as available from the British National Formulary (46) or the summary of product characteristics (47). The OMED for each product was multiplied by the number of prescriptions issued each year to determine the annual totals. Results were stratified by drug, with less frequently used medicines grouped as 'other' opioids. This included diamorphine (oral preparations), dipipanone, hydromorphone, meptazinol, methadone (tablets), pentazocine, pethidine and tapentadol.

A secondary analysis used proxy-OMED totals for products which had a daily dose of 120mg OMED or more, classed as 'high dose' opioid prescribing (8).

Deprivation scores

The Welsh Index of Multiple Deprivation (WIMD) is the official measure used by Welsh Government to determine relative deprivation of areas within Wales (40). The WIMD is a weighted total score of deprivation based on income (23.5%), employment (23.5%), health (14%), education (14%), geographical access of services (10%), community safety (5%), physical environment (5%) and housing (5%). Scores are not linear, so areas in group 2 are not twice as deprived as those in group 4. Indices are published every 3 years. The 2011 Index was used for this study. Data are presented in quintiles, with WIMD1 being the most deprived areas and WIMD5 the least deprived.

Measuring utilisation

The number of prescriptions and number of patients per year, per drug were calculated in repeat, cross-sections for each year and further stratified into drug and deprivation group. Data were standardised to annual population size using data

from the Office of National Statistics (ONS) (48) and StatsWales (49). Deprivation data was adjusted by each quintile's annual population.

Data analysis

Data was extracted from the study tables within SAIL using Structured Query Language-code searches in Eclipse software. Trends were reported standardised per 1000 population. Percentage change rate of number of prescriptions issued and number of people receiving prescriptions over the study period were also noted. Data was stratified into 8 groups. The 7 most commonly prescribed drugs were buprenorphine, codeine, dihydrocodeine, fentanyl, morphine, oxycodone and tramadol. The 'other' group included dextropropoxyphene, meptazinol, pethidine and tapentadol. Statistical analysis was conducted using SPSS 25 software and figures drawn using Excel 16.30.

Patient and public involvement statement

There was no direct patient involvement in development and design of this study. However, the SAIL databank has members of the public who provide advice and give recommendations on safeguarding and ethical approval via a Consumer Panel. Panel members also provide input to the IGRP, which approves all data applications.

Results

Prescribing data were extracted from 345 of the 443 (78%) Primary Care General Practices in Wales. A total of 22 641 424 prescriptions for opioids were included in this analysis. Between 2005 and 2015, the number of opioid prescriptions increased by 44% from 692 to 994 prescriptions per 1000 population annually. The total daily OMED, issued in all included practices in Wales doubled in the 11 years examined, rising from 37 662 651 mg to 76 428 768 mg. When adjusted to population, daily OMED per 1000 population increased by 94.7% (from 16 266 mg to 31 665 mg) over the study period (**Table 1**).

| | Oral or transdermal opioids | | | | Products with a daily dose >120mg OMED | | |
|----------------------------|--|---|--|---|---|---|--|
| | Annual total daily oral morphine equivalent (mg) dose prescribed | Annual total daily oral morphine equivalent dose (mg) per 1000 population | Oral morphine equivalent dose per prescription issued (mg) | Annual number of prescriptions issued per 1000 population | Annual total daily oral morphine equivalent dose (mg) | Annual total daily oral morphine equivalent dose (mg) per 1000 population | Annual total daily oral morphine equivalent dose (mg) per prescription |
| Buprenorphine | | | | | | | |
| 2005 | 977 464 | 422 | 98 | 4 | 474 808 | 205 | 136 |
| 2015 | 2 756 458 | 1 142 | 37 | 31 | 817 904 | 339 | 139 |
| Percentage/rate change (%) | 182.0 | 170.5 | -61.7 | 606.3 | 72.3 | 65.3 | 2.5 |
| Codeine | | | | | | | |
| 2005 | 13 743 115 | 5 916 | 17 | 357 | - | - | - |
| 2015 | 25 593 382 | 10 581 | 19 | 549 | - | - | - |
| Percentage/rate change (%) | 86.2 | 78.8 | 16.2 | 53.9 | - | - | - |
| Dihydrocodeine | | | | | | | |
| 2005 | 4 368 806 | 1 887 | 12 | 154 | - | - | - |
| 2015 | 3 471 460 | 1 438 | 13 | 109 | - | - | - |
| Percentage/rate change (%) | -20.5 | -23.8 | 7.7 | -29.2 | - | - | - |
| Fentanyl | | | | | | | |
| 2005 | 2 695 290 | 1 164 | 186 | 6 | 2 173 920 | 939 | 244 |
| 2015 | 6 496 270 | 2 691 | 147 | 18 | 4 712 410 | 1 952 | 259 |
| Percentage/rate change (%) | 141.0 | 131.2 | -21.2 | 193.2 | 116.8 | 108.0 | 6.5 |
| Morphine | | | | | | | |
| 2005 | 3 293 220 | 1 422 | 86 | 17 | 2 554 920 | 1 103 | 135 |
| 2015 | 17 047 800 | 7 063 | 68 | 104 | 11 572 760 | 4 795 | 127 |
| Percentage/rate change (%) | 417.7 | 396.6 | -20.6 | 525.6 | 353.0 | 334.5 | -5.5 |
| Oxycodone | | | | | | | |
| 2005 | 1 316 480 | 569 | 105 | 5 | 872 240 | 377 | 179 |
| 2015 | 6 165 400 | 2 554 | 100 | 26 | 4 003 400 | 1 659 | 184 |
| Percentage/rate change (%) | 368.3 | 349.3 | -4.9 | 372.4 | 359.0 | 340.3 | 2.8 |
| Tramadol | | | | | | | |
| 2005 | 7 865 695 | 3 397 | 36 | 95 | - | - | - |
| 2015 | 14 252 335 | 5 905 | 38 | 156 | - | - | - |
| Percentage/rate change (%) | 81.2 | 73.8 | 5.7 | 64.4 | - | - | - |
| Other | | | | | | | |
| 2005 | 3 446 735 | 1 719 | 27 | 56 | 2 0400 | 9 | 47 |
| 2015 | 699 711 | 347 | 58 | 5 | 339 700 | 141 | 137 |
| Percentage/rate change (%) | -79.7 | -79.8 | 117.4 | -91.0 | 1 565.2 | 1 497.5 | 190.6 |

Table 1: Daily oral morphine equivalent dose (mg) issued on prescription, given as annual totals and adjusted to population, stratified by drug

Codeine was the most commonly prescribed opioid, with just under 12.5 million prescriptions issued and the highest annual total OMED prescribed for the study duration (**Figure 1**). Its OMED per 1000 population increased by 79%, from 5916 mg to 10 581 mg. Tramadol was the second most commonly prescribed opioid in Wales. Its use increased by 74%, from 3397 mg to 5905 mg OMED per 1000 population, although annual total OMED reduced from 2014 (**Figure 1**).

Large increases were noted in 'strong' opioids (morphine, oxycodone, fentanyl and buprenorphine) during the study (**Figure 1**). Morphine OMED increased by 397%, from 1422mg to 7063mg per 1000 population. By 2015, morphine was prescribed around 3 times the equivalent dose of either oxycodone (increased 349%, from 569mg to 2554mg per 1000 population) or fentanyl (increased 131%, from 1164mg to 2 691mg per 1000 population). Morphine OMED was around 6 times that of buprenorphine, which itself increased 171%, from 422 to 1142mg per 1000 population.

Overall, 71% of the total opioid burden in the areas of Wales covered by the SAIL databank was accounted for by 3 drugs; codeine (35%), tramadol (22%) and morphine (14%). Total OMED for each drug, prescribed over the 11-year study period, were statistically different to each other ($p < 0.001$, $H = 73.5$, $\eta^2 = 0.8$). Post-hoc analysis confirmed differences between total OMEDs of codeine compared to dihydrocodeine ($p < 0.001$), buprenorphine ($p < 0.001$), oxycodone ($p < 0.001$) and the 'other' category of opioids ($p < 0.001$). Tramadol OMED demonstrated significant differences when compared to buprenorphine ($p < 0.001$), oxycodone ($p < 0.05$) and 'other' opioids ($p < 0.001$). Morphine OMED was statistically different to buprenorphine ($p < 0.05$) and the 'other' category ($p < 0.001$).

Oral morphine equivalent dose per prescription

Between 2005 and 2015, for all opioids, OMED per prescription increased by 36%, from 23mg to 32mg. Analysis of the eight drug groups demonstrated a statistically significant difference in OMED per prescription, largely between weak and strong opioids ($p < .001$, $H = 82.4$, $\eta^2 = 0.9$).

Despite the large increases in the number of prescriptions issued, OMED per prescription reduced for the four main 'strong' opioids, morphine (-21%, from 86mg to 68mg), oxycodone (-5%, from 105mg to 100mg), fentanyl (-21%, from 186mg to 147mg) and buprenorphine (-62%, from 98mg to 37mg), (**Table 1**). Buprenorphine OMED reduction resulted from falling use of twice-weekly, higher dose patches (>35micrograms per hour), which outweighed the higher number of prescriptions for lower dose weekly patches (5-20 micrograms per hour).

Whilst the number of prescriptions for 'other' opioids decreased by 91% (from 56 to 5 per 1000 population) over the study period, the OMED per prescription more than doubled from 27mg to 58mg per prescription. Prescription numbers notably increased from 2011 onwards, when tapentadol was released onto the UK market. Codeine, dihydrocodeine and tramadol dose per prescription increased over the 11 year period.

High dose opioid prescribing

Based on the strength of preparation prescribed, five groups of drugs demonstrated dosing of 120mg OMED and over between 2005 and 2015 (**Table 1**). When compared to the total OMED prescribed in the study period, statistically significant differences were established between them ($p=0.000$, $H=45.7$, $\eta^2=0.8$). High-dose fentanyl OMED was confirmed to be significantly larger than OMED for buprenorphine ($p<0.001$), morphine ($p<0.001$) and 'other' opioids ($p<0.001$), as was oxycodone OMED when compared to morphine ($p<0.005$) and 'other' opioids ($p<0.001$).

Whilst morphine (335% increase from 1103mg to 4795mg per 1000 population) and oxycodone (340% increase from 377mg to 1659mg per 1000 population) saw similar percentage increases, the total OMED for high-dose morphine was nearly three times that of oxycodone throughout the study (**Figure 2**). The large percentage increase in 'other' opioids prescribed at 120mg OMED or above (1497% from 9mg to 141mg per 1000 population) was entirely due to tapentadol prescribing from 2011 onwards. Tapentadol prescribing tended to be at high OMED levels.

Opioid prescribing trends by deprivation

The trends in annualised daily OMED of all oral and transdermal opioids stratified by the Welsh Index of Multiple Deprivation (WIMD2011) are illustrated in Figure 3. Over the 11 years of the study, the most deprived areas (WIMD1) examined were prescribed 100 711 696mg more OMEDs than the least deprived (WIMD5) (**Table 2**).

Between 2005 and 2015, OMED doubled in all but the least deprived (WIMD5) areas (**Table 2**), with 28% (176 824 265mg of 622 969 068mg) of the total OMED prescribed issued in the most deprived areas of Wales. In contrast, 12% (76 112 569mg) were prescribed in the least deprived areas. Throughout the study, the OMED prescribed in WIMD1 areas remained more than twice those noted in WIMD5 areas (**Table 2**) for both total OMED (mg) and OMED per 1000 population. Despite large percentage increases in all quintiles, the total OMED prescribed in each area was significantly different ($p < 0.001$, $H = 34.5$, $\eta^2 = 0.61$). The least deprived areas had significantly lower prescribed OMED than quintiles 1 to 3 (WIMD1 $p < 0.001$, WIMD2 $p < 0.001$ and WIMD3 $p < 0.05$). The total OMED prescribed in the most deprived areas (WIMD1) was significantly higher compared to that in WIMD4 areas ($p < 0.05$).

| | | Oral or transdermal opioids | | | Products with a daily >120mg OMED | | | |
|--------------|-----------------------------------|---|--|---|--|--|---|--|
| | | Oral morphine equivalent dose (mg) prescribed | Oral morphine equivalent dose (mg) per 1000 population | Oral morphine equivalent dose (mg) per prescription | Oral morphine equivalent dose (mg) per day | Total oral morphine equivalent dose (mg) per 1000 population | Oral morphine equivalent dose (mg) per prescription | Oral morphine equivalent dose (mg) per person issued prescriptions |
| WIMD1 | 2005 | 10 319 636 | 21 757 | 22 | 1 466 652 | 3092 | 166 | 822 |
| | 2015 | 21 167 919 | 43 176 | 31 | 5 674 237 | 11574 | 152 | 1111 |
| | Percentage/rate change (%) | 105.1 | 98.4 | 41.0 | 286.9 | 274.3 | -7.8 | 35.2 |
| | Total prescribed | 176 824 265 | | | 37 943 319 | | | |
| WIMD2 | 2005 | 8 590 375 | 18 203 | 24 | 1 208 800 | 2561 | 162 | 834 |
| | 2015 | 17 399 026 | 35 475 | 32 | 4 837 285 | 9863 | 158 | 1078 |
| | Percentage/rate change (%) | 102.5 | 94.9 | 36.3 | 300.2 | 285.0 | -2.5 | 29.3 |
| | Total prescribed | 146 459 878 | | | 32 622 635 | | | |
| WIMD3 | 2005 | 7 684 060 | 17 108 | 24 | 1 373 446 | 3058 | 175 | 847 |
| | 2015 | 15 342 942 | 32 564 | 33 | 4 642 419 | 9853 | 155 | 1010 |
| | Percentage/rate change (%) | 99.7 | 90.3 | 33.1 | 238.0 | 222.2 | -11.4 | 19.2 |
| | Total prescribed | 129 880 669 | | | 33 344 376 | | | |
| WIMD4 | 2005 | 5 374 595 | 12 242 | 25 | 1 104 120 | 2515 | 188 | 911 |
| | 2015 | 10 878 897 | 23 534 | 33 | 3 314 817 | 7171 | 157 | 988 |
| | Percentage/rate change (%) | 102.4 | 92.2 | 28.9 | 200.2 | 185.1 | -16.5 | 8.5 |
| | Total prescribed | 93 691 687 | | | 25 420 454 | | | |
| WIMD5 | 2005 | 4 486 035 | 9 381 | 24 | 697 496 | 1459 | 163 | 662 |
| | 2015 | 8 721 170 | 17 557 | 30 | 2 228 629 | 4487 | 154 | 829 |
| | Percentage/rate change (%) | 94.4 | 87.2 | 27.9 | 219.5 | 207.6 | -5.5 | 25.2 |
| | Total prescribed | 76 112 569 | | | 16 958 635 | | | |

Table 2: Trends in oral morphine equivalent prescribing stratified by deprivation (Welsh Index of Multiple Deprivation WIMD2011). WIMD1=most deprived, WIMD5=least deprived

OMED per prescription

OMEDs per prescription were similar in all quintiles, despite the large differences in the actual number of prescriptions issued (**Figure 3**). The percentage change in OMED per prescription increased with greater deprivation, with WIMD1 areas seeing increases of 41%, from 22mg to 31mg per prescription, whereas WIMD5 areas increased by 28%, from 24mg to 30mg per prescription between 2005 and 2015. No statistically significant difference in the total OMED per prescription between deprivation quintiles was found ($p>0.05$, $H=5.3$, $\eta^2=0.03$).

OMED per person

Oral morphine equivalent dose per person was significantly different between quintiles ($p<0.05$, $H=11.1$, $\eta^2=0.6$) (**Table 2**). The OMED per person was confirmed to be significantly greater in the two most deprived areas (WIMD1 $p<0.05$, WIMD2 $p<0.05$) compared to the least deprived quintile (WIMD5). In WIMD1 areas, a 79% increase led the dose per person to rise from 96mg to 173mg in 11 years. Smaller increases were seen in WIMD2 (70%, from 99mg to 169mg per person), WIMD3 (65%, from 98mg to 161mg per person), WIMD4 (61%, from 93mg to 151mg per person). A 60% increase in WIMD5 areas, from 80mg to 128mg per person resulted in a 35% difference in OMED per prescription between the least and most deprived areas in Wales.

High-dose opioid prescribing by deprivation

The total OMED prescribed for products with a daily OMED of 120mg and over tripled in each deprivation quintile between 2005 and 2015 (**Table 2**). As observed with all opioid prescribing, the most deprived areas had the greatest high-dose OMED prescribed. The total of 37 943 319mg prescribed over 11 years was 2.24 times more than in the least deprived quintile, where 16 958 635mg were prescribed in the same period. The differences between high-dose OMED in each quintile were found to be statistically significant with small effect size ($p=0.002$, $H=17.1$, $\eta^2=0.26$). The total high-dose OMED in the WIMD5 areas was significantly different to those in WIMD1 ($p<0.05$), WIMD2 ($p<0.05$) and WIMD3 ($p<0.05$) areas.

After adjustment for population size per quintile, the large differences in OMED per 1000 population dependent on the level of deprivation were maintained with significant differences, although small effect size ($p=0.001$, $H18.5$, $\eta^2=0.29$). OMED per 1000 population was significantly lower in the least deprived areas of Wales compared to quintiles 1 to 3, all with $p<0.05$. In 2015, around 17% more high-dose OMED was prescribed in WIMD1 areas (11574mg per 1000 population) than in the next most deprived WIMD2 (9863mg per 1000 population). Even though high-dose OMED between 2005 and 2015 tripled in WIMD5 areas, OMED prescribed was still 156% higher in WIMD1 areas at the end of the study (**Figure 4**).

Discussion

The results of this retrospective database study demonstrate a marked increase in opioid burden in Wales between 2005 and 2015. The rate of increase slowed toward the end of the study period. An increase of 44% in the number of opioid prescriptions per 1000 population between 2005 and 2015 in Wales has been reported (4). Using the proxy measure of OMED described, the opioid burden on the population over the study period nearly doubled.

The data demonstrates the disproportionate opioid burden felt by people living in the most deprived areas of Wales. Increasing deprivation was linked to the receipt of higher doses, higher OMED and a higher opioid burden per person. Whilst rises in percentage terms were similar in all WIMD2011 quintiles, significant differences were consistent between the most and least deprived areas throughout the 11 years examined without evidence that the trend was beginning to change.

Despite a low OMED per prescription, codeine is used widely throughout Wales and places a major burden on the population. Morphine was the most burdensome strong opioid, although both oxycodone and fentanyl had higher OMED (mg) per prescription issued.

This study identified rising trends in opioid prescribing in Wales, similar to those previously reported in other parts of the UK (1,3,6,32,33,50).

Examining trends by prescription numbers alone is likely to underestimate the opioid burden within a population. Curtis et al demonstrated a 34% growth in prescription numbers resulted in a 127% increase in OMED burden (6). Similarly, as shown in this study, a 44% increase in prescription numbers in Wales translated into a 95% increase in opioid burden using the proxy-OMED measure described.

Codeine is referenced as a 'weak' opioid (8,46) and its risks may therefore be downplayed. However, deaths in Wales associated with codeine, including as part of compound preparations (e.g. co-codamol), increased from 12 in 2005 to 16 in 2015 (51). Furthermore, following the end of the study period, codeine-associated deaths increased a further 50%, with 24 reported fatal incidents in 2018, making codeine responsible for 15% of opioid associated deaths in Wales in 2018 (n=164) (51). Since codeine is also available to purchase over-the-counter (OTC), prescribing data is an underestimate of population exposure to the drug (31, 52)

Higher OMED per prescription for non-morphine strong opioids may point to prescribers misunderstanding oral morphine equivalence (53-55) and using higher doses of non-morphine opioids than are recommended (8). Tapentadol was responsible for a rapid increase in OMED for 'other' opioids since its introduction to the UK market in 2011. This has been noted in England as well (6). By the end of the study period, high dose tapentadol OMED per prescription was greater than that of morphine.

This study has demonstrated substantial increases in opioid prescribing, with higher levels in more deprived populations, which was also previously reported in England (2,33) and internationally (56-59). Furthermore, much of the focus of the opioid crisis in the US has been on rural, deprived communities where access to, and affordability of, healthcare services and social support are poor (35,56,60).

Increased levels of prescribing in areas of high socio-economic deprivation have been linked to greater reported pain intensity (32). However, limited evidence supports the notion that opioids are effective at reducing pain, particularly in the longer term (8,18,61). High-dose opioids (above 120mg OMED) have also been associated with increased levels of pain (62,63). In the context of this and previous

studies (2,6,32,33, the implications of the increased prescribing of opioids in more deprived areas are concerning as it exposes the most vulnerable people to higher levels of medicines that may be ineffective at best and may even cause additional health and well-being complications (11).

This study is the first to utilise a large dataset including routine data from 78% of Primary Care practices in Wales to map opioid prescribing trends (4). Large sets of prescribing and diagnostic data have been validated as an accurate means for conducting healthcare population research (64,65) as they reduce recall bias and regional variation. Moreover, any person registered with included practices and prescribed an opioid medicine was included in the analysis, thus avoiding selection bias. Furthermore, this is the first study conducted using Welsh data that utilised an OMED measure to better understand the burden of opioid prescribing on the population. Using the linkage systems within SAIL datasets, data from people with a recorded cancer diagnosis, could be excluded from analysis. While recent studies of opioid prescribing in the UK based on large datasets merely assumed that the majority of prescribing was attributable to persisting, non-cancer pain based on the longevity of prescribing and the dose forms used (2,6,50), this data confidently reflects prescribing for non-cancer pain.

However, prescribing data alone provides an indication of intention to treat but does not confirm consumption. It also does not give an indication of the diagnosis or how long an individual might have been using the medication. Moreover, the data presented here did not identify people receiving more than one opioid medicine and who would have a higher individual OMED burden.

It was not possible to access linked dispensing data, which would provide the detail required to more accurately calculate OMED. This resulted in the development of a proxy measure which provides a daily estimation of OMED, multiplied by the number of prescriptions as described above, and required a number of assumptions to be made. Without knowing prescription duration, i.e. how many daily doses were provided per prescription, the annualised OMEDs presented here may be an underestimation of the opioid burden. However, the trends described are similar to those reported elsewhere in the UK (1-3,6,33,50).

For this study, opioid medicines were identified by read codes and accuracy of the data extraction depended on the inclusivity of the coding used. Incomplete coding lists would result in data being lost to the analysis and could lead to an under-representation of prescribing. Also, oral and transdermal medicines were selected on the likelihood of them being used for pain management rather than the management of misuse disorder. For example, high dose sublingual buprenorphine and methadone solution were excluded. However, in rare cases, these may be prescribed as analgesia while other included opioid preparations could be used as part of misuse management. Again, this could result in an over or underestimation of prescribing. However, similar rationales for deciding which opioid products to include in analysis of Primary Care prescribing was adopted by other UK-based authors (1,3,6,33).

Using a measure of opioid burden, such as oral morphine equivalent dose gives a more accurate measure of the impact of opioid prescribing on a population. In Wales, National Prescribing Indicators are set each year by the All Wales Medicines Strategy Group (AWMSG) (66) using average daily quantities (ADQ) as the measure. ADQ is the assumed average maintenance dose per day for a drug, used for its main indication in adults. The risks of opioids are known to increase above a daily dose of 120mg OMED (8), regardless of the indication. Consequently, using a consistent measure such as OMED would provide greater understanding of the risks imposed on the population. In addition, good practice, such as using weekly prescriptions for people trialling or tapering opioids and those at risk of misuse (8), would not skew data as it does currently.

Welsh Government recently set out plans to improve access to persistent pain management support across Wales (67). It focusses on improving access to non-pharmacological and self-management support such as pain management programmes (68,69), psychological input (70) and physiotherapy (71) which have been demonstrated to have longer-term benefits and do not carry the same risks as opioids. However, as with other guidelines in this area (72, 73), the document does not include a strategy to address health inequalities in pain management support per se (64). Given the disproportionate use of opioids in the most deprived areas, it

would seem essential to tackle the root causes of those differences, if anything is to improve. More research is needed to better understand the reasons opioids are still prescribed in the face of mounting evidence of harm including current concerns around dependence and misuse (8,11,31). Furthermore, greater understanding of why people living with pain continue to use opioids in spite of poor effect or additional health concerns is required.

Supporting non-pharmacological management is essential to enable people to live well with pain (74) but can be difficult to encourage in practice (75). McCrorie and colleagues (2015) concluded that problematic opioid prescribing can result from failing to meet the self-perceived needs of people living with pain and from prescribers feeling unable to negotiate alternatives (76). This was echoed by Finestone who described opioid prescribing as a surrogate for poor access to pain management support (77).

It would seem that more targeted use of resources into Primary Care, and particularly in areas of greater deprivation, would be a prudent way of improving lives and tackling the use of opioid medicines that can cause so much harm.

Contributors

ED conceived of and designed the study, collated the read-codes used for data extraction, devised the OMED proxy-measure and coded the extracted data, undertook the data analysis, drafted and revised the manuscript. BS oversaw the study design and data analysis and critically revised the manuscript. MJ oversaw the study design and statistical analysis and critically revised the manuscript. CP and JR oversaw the study design and critically revised the manuscript. All authors read and approved the final manuscript.

Acknowledgements

This study makes use of anonymized data generated by the Secure Anonymized Information Linkage (SAIL) system, which is part of the national [e-health](#) records research infrastructure for Wales. We would like to acknowledge all the data providers who make anonymized data available for research.

Funding statement

This work was supported by Pharmacy Research UK grant number PRUK-2016-PA1-A. ED's PhD is partly supported by funding from Research Capacity Building Collaboration.

Competing interests

None declared

Patient consent for publication

Not required

Data sharing statement

Dataset available from the Dryad repository, DOI:

<https://doi.org/10.5061/dryad.1rn8pk0pf>

Patient and Public Involvement statement

This research was done without patient involvement. Patients were not invited to comment on the study design and were not consulted to develop patient relevant outcomes or interpret the results. Patients were not invited to contribute to the writing or editing of this document for readability or accuracy.

References

1. Zin CS, Chen LC, Knaggs RD. Changes in trends and pattern of strong opioid prescribing in primary care. *European Journal of Pain*. 2014 Oct;18(9):1343–51.
2. Mordecai L, Reynolds C, Donaldson LJ, de C Williams AC. Patterns of regional variation of opioid prescribing in primary care in England: a retrospective observational study. *Br J Gen Pract*. 2018 Mar;68(668):e225–33.
3. Ruscitto A, Smith BH, Guthrie B. Changes in opioid and other analgesic use 1995-2010: repeated cross-sectional analysis of dispensed prescribing for a large geographical population in Scotland. *European Journal of Pain*. 2015 Jan;19(1):59–66.
4. Davies E, Phillips C, Rance J, Sewell B. Examining patterns in opioid prescribing for non-cancer-related pain in Wales: preliminary data from a retrospective cross-sectional study using large datasets. *British Journal of Pain*. 2018 Sep 25;136(9):204946371880073–14.
5. Bedson J, Chen Y, Hayward RA, Ashworth J, Walters K, Dunn KM, et al. Trends in long-term opioid prescribing in primary care patients with musculoskeletal conditions: An observational database study. *Pain*. 2016 Jul 1;157(7):1525–31.
6. Curtis HJ, Croker R, Walker AJ, Richards GC, Quinlan J, Goldacre B. Opioid prescribing trends and geographical variation in England, 1998–2018: a retrospective database study. *Lancet Psychiatry*. 2019 Feb 1;6(2):140–50.
7. Stannard C. Where now for opioids in chronic pain? *Drug Ther Bull*. 2018 Oct;56(10):118–22.
8. Faculty of Pain Medicine, Royal College of Anaesthetists. Opioids Aware: A resource for patients and healthcare professionals to support prescribing of opioid medicines for pain [Internet]. Stannard C, Knaggs R, editors. fpm.ac.uk. [cited 2016 Oct 31]. Available from: <https://www.fpm.ac.uk/faculty-of-pain-medicine/opioids-aware>
9. Rosenblum A, Marsch LA, Joseph H, Portenoy RK. Opioids and the Treatment of Chronic Pain: Controversies, Current Status, and Future Directions. *Exp Clin Psychopharmacol*. 2008 Oct 1;16(5):405–16.
10. Ballantyne JC, Shin NS. Efficacy of Opioids for Chronic Pain. *Clin J Pain*. 2008 Jul;24(6):469–78.
11. Els C, Jackson TD, Kuyk D, Lappi VG, Sonnenberg B, Hagtvedt R, et al. Adverse events associated with medium- and long-term use of opioids for chronic non-cancer pain: an overview of Cochrane Reviews. *Cochrane Database Syst Rev*. 2017 Oct 30;10(10):CD012509.

12. Dependence and withdrawal associated with some prescribed medicines: an evidence review. Sep 5, 2019 pp. 1–152.
13. Weisberg D, Stannard C. Lost in translation? Learning from the opioid epidemic in the USA. *Anaesthesia*. 2013 Dec;68(12):1215–9.
14. Weisberg DF, Becker WC, Fiellin DA, Stannard C. Prescription opioid misuse in the United States and the United Kingdom: cautionary lessons. *Int J Drug Policy*. 2014 Nov;25(6):1124–30.
15. Scherrer JF, Salas J, Copeland LA, Stock EM, Ahmedani BK, Sullivan MD, et al. Prescription opioid duration, dose, and increased risk of depression in 3 large patient populations. *Ann Fam Med*. 2016 Jan 1;14(1):54–62.
16. Mazereeuw G, Sullivan MD, Juurlink DN. Depression in chronic pain: might opioids be responsible? *Pain*. 2018 Nov;159(11):2142–5.
17. Seyfried O, Hester J. Opioids and endocrine dysfunction. *British Journal of Pain*. SAGE Publications; 2012 Feb 1;6(1):17–24.
18. Furlan AD, Sandoval JA, Mailis-Gagnon A, Tunks E. Opioids for chronic noncancer pain: a meta-analysis of effectiveness and side effects. *CMAJ. Canadian Medical Association*; 2006 May 23;174(11):1589–94.
19. Dependence and withdrawal associated with some prescribed medicines: an evidence review. Sep 5, 2019 pp. 1–152.
20. Campbell G, Nielsen S, Larance B, Bruno R, Mattick R, Hall W, et al. Pharmaceutical Opioid Use and Dependence among People Living with Chronic Pain: Associations Observed within the Pain and Opioids in Treatment (POINT) Cohort. *Pain Med*. 2015 Sep;16(9):1745–58.
21. Lin JC, Chu LF, Stringer EA, Baker KS, Sayyid ZN, Sun J, et al. One month of oral morphine decreases gray matter volume in the right amygdala of individuals with low back pain: Confirmation of previously reported magnetic resonance imaging results. *Pain Med*. 2016 Aug 1;17(8):1497–504.
22. Scherrer JF, Salas J, Sullivan MD, Schneider FD, Bucholz KK, Burroughs T, et al. The influence of prescription opioid use duration and dose on development of treatment resistant depression. *Prev Med*. 2016 Oct 1;91:110–6.
23. Gomes T, Mamdani MM, Dhalla IA, Paterson JM, Juurlink DN. Opioid Dose and Drug-Related Mortality in Patients With Nonmalignant Pain. *Archives of Internal Medicine. American Medical Association*; 2011 Apr 11;171(7):686–91.
24. Merrill JO, Korff Von M, Banta-Green CJ, Sullivan MD, Saunders KW, Campbell CI, et al. Prescribed opioid difficulties, depression and opioid

- dose among chronic opioid therapy patients. *Gen Hosp Psychiatry*. 2012 Nov;34(6):581–7.
25. Morasco BJ, Yarborough BJ, Smith NX, Dobscha SK, Deyo RA, Perrin NA, et al. Higher Prescription Opioid Dose is Associated With Worse Patient-Reported Pain Outcomes and More Health Care Utilization. *The Journal of Pain*. Elsevier Inc; 2017 Apr 1;18(4):437–45.
 26. Salas J, Scherrer JF, Schneider FD, Sullivan MD, Bucholz KK, Burroughs T, et al. New-onset depression following stable, slow, and rapid rate of prescription opioid dose escalation. *Pain*. 2017 Feb 1;158(2):306–12.
 27. Fischer B, Murphy Y, Kurdyak P, Goldner EM. Depression - A major but neglected consequence contributing to the health toll from prescription opioids? *Psychiatry Res*. 2016 Sep 30;243:331–4.
 28. Ballantyne JC, LaForge KS. Opioid dependence and addiction during opioid treatment of chronic pain. *Pain*. 2007 Jun;129(3):235–55.
 29. Minozzi S, Amato L, Davoli M. Development of dependence following treatment with opioid analgesics for pain relief: a systematic review. *Addiction*. 2013 Apr;108(4):688–98.
 30. Degenhardt L, Lintzeris N, Campbell G, Bruno R, Cohen M, Farrell M, et al. Experience of adjunctive cannabis use for chronic non-cancer pain: Findings from the Pain and Opioids IN Treatment (POINT) study. *Drug and Alcohol Dependence*. Elsevier Ireland Ltd; 2015 Feb 1;147:144–50.
 31. Taylor S, Annand F, Burkinshaw P, Greaves F, Kelleher M, Knight J, et al. Dependence and withdrawal associated with some prescribed medicines: an evidence review. 2019 Sep pp. 1–152.
 32. Todd A, Akhter N, Cairns J-M, Kasim A, Walton N, Ellison A, et al. The Pain Divide: a cross-sectional analysis of chronic pain prevalence, pain intensity and opioid utilisation in England. *BMJ Open*. 2018 Sep 11;8(7):e023391.
 33. Chen T-C, Chen L-C, Kerry M, Knaggs RD. Prescription opioids: Regional variation and socioeconomic status - evidence from primary care in England. *Int J Drug Policy*. 2019 Feb; 64:87–94.
 34. Torrance N, Mansoor R, Wang H, Gilbert S, Macfarlane GJ, Serpell M, et al. Association of opioid prescribing practices with chronic pain and benzodiazepine co-prescription: a primary care data linkage study. *Br J Anaesth*. 2018 Jun;120(6):1345–55.
 35. Keyes KM, Cerdá M, Brady JE, Havens JR, Galea S. Understanding the rural-urban differences in nonmedical prescription opioid use and abuse in the United States. *American Journal of Public Health*. 2014 Feb 1;104(2):e52–9.

36. Marmot M, Bell R. Fair society, healthy lives. *Public Health*. 2012 Sep;126 Suppl 1(SUPPL.1):S4–S10.
37. Stannard CF. Pain and pain prescribing: what is in a number? *Br J Anaesth*. 2018 Jun;120(6):1147–9.
38. Edwards RT, Charles JM, Thomas S, Bishop J, Cohen D, Groves S, et al. A national Programme Budgeting and Marginal Analysis (PBMA) of health improvement spending across Wales: disinvestment and reinvestment across the life course. *BMC Public Health*. 1st ed. 2014 Aug 12;14(1):837.
39. Barnard H. Poverty in Wales 2018 [Internet]. Available from: <https://www.jrf.org.uk>
40. Wales SF. Welsh Index of Multiple deprivation 2011 [Internet]. 2011. 15 p. Available from: <http://gov.wales/docs/statistics/2011/110922wimd11guidanceen.pdf>
41. Office for National Statistics. Deaths related to drug poisoning in England and Wales: 2018 registrations [Internet]. 2019 Aug pp. 1–12. Available from: <https://www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarriages/deaths/bulletins/deathsrelatedtodrugpoisoninginenglandandwales/2018registrations>
42. Holloway K, Hills R, May T. Fatal and non-fatal overdose among opiate users in South Wales: A qualitative study of peer responses. *Int J Drug Policy*. 2018 Jun 1;56:56–63.
43. Lyons RA, Jones KH, John G, Brooks CJ, Verplancke J-P, Ford DV, et al. The SAIL databank: linking multiple health and social care datasets. *BMC Med Inform Decis Mak*. 2009 Jan 16;9(1):3.
44. Ford DV, Jones KH, Verplancke J-P, Lyons RA, John G, Brown G, et al. The SAIL Databank: building a national architecture for e-health research and evaluation. *BMC Health Services Research*. 2009 Sep 4;9:157.
45. NHS Wales. General Practice Prescribing Data Extract. <http://www.primarycareservices.wales.nhs.uk/general-practice-prescribing-data-extrac> (Accessed October 2019).
46. British National Formulary. Prescribing in Palliative Care. <https://bnf.nice.org.uk/guidance/prescribing-in-palliative-care.html> (Accessed September 2019)
47. Electronic Medicines Compendium: Summary of Product Characteristics. (<https://www.medicines.org.uk/emc> Accessed September 2019).
48. Office for National Statistics. 2011 Census Analysis - Comparing Rural and Urban Areas of England and Wales. 2015 Oct pp. 1–43.

49. Welsh Government, Wales S. 2014 Mid-year Population Estimates for Wales. Cardiff; 2015 Jun pp. 1–8. Report No.: SB 34/2015.
50. Foy R, Leaman B, McCrorie C, Petty D, House A, Bennett M, et al. Prescribed opioids in primary care: cross-sectional and longitudinal analyses of influence of patient and practice characteristics. *BMJ Open*. 2016 May 13;6(5):e010276.
51. Office of National Statistics. Deaths related to drug poisoning by selected substances.
<https://www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarriages/deaths/datasets/deathsrelatedtodrugpoisoningbyselectedsubstances> (Accessed September 2019)
52. Connelly D. Breakdown of the OTC medicines market in Britain. *The Pharmaceutical Journal*, May 2018, Vol 300, No 7913, online |DOI: 10.1211/PJ.2018.20204913.
53. Rennick A, Atkinson T, Cimino NM, Strassels SA, McPherson ML, Fudin J. Variability in opioid equivalence calculations. *Pain Med*. 2016 May 1;17(5):892–8.
54. Shaheen PE, Walsh D, Lasheen W, Davis MP, Lagman RL. Opioid Equianalgesic Tables: Are They All Equally Dangerous? *Journal of Pain and Symptom Management*. 2009 Sep 1;38(3):409–17.
55. Institute for Safe Medication Practices Canada. ISMP Canada Safety Bulletin. Sink or Swim? 2017 Sep 28;17(8):1–6. Available from: http://www.ismp-canada.org/err_index.htm
56. Joynt M, Train MK, Robbins BW, Halterman JS, Caiola E, Fortuna RJ. The Impact of Neighborhood Socioeconomic Status and Race on the Prescribing of Opioids in Emergency Departments Throughout the United States. *J GEN INTERN MED*. 2013 Jun 25;28(12):1604–10.
57. Wagemakers FN, Hollingworth SA, Kreijkamp-Kaspers S, Tee EHL, Leendertse AJ, van Driel ML. Opioid analgesic use in Australia and The Netherlands: a cross-country comparison. *Int J Clin Pharm*. Springer International Publishing; 2017 Aug;39(4):874–80.
58. Kapoor S, Thorn BE. ORIGINAL RESEARCH. Healthcare use and prescription of opioids in rural residents with pain. 14(3):1–1212p. Available from: <http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=103896597&site=ehost-live&scope=site&authtype=shib&custid=s8000044>
59. Prunuske JP, St Hill CA, Hager KD, Lemieux AM, Swanoski MT, Anderson GW, et al. Opioid prescribing patterns for non-malignant chronic pain for rural versus non-rural US adults: a population-based study using 2010 NAMCS data. *BMC Health Services Research*. 2014 Nov 19;14(1):972–8.

60. Rigg KK, Monnat SM, Chavez M. Opioid-related mortality in rural America: geographic heterogeneity and intervention strategies. Elsevier
61. Chaparro LE, Furlan AD, Deshpande A. Opioids compared with placebo or other treatments for chronic low back pain: an update of the Cochrane Review. *Spine (Phila Pa 1976)*. 2014.
62. Cohen SP, Christo PJ, Wang S, Chen L, Stojanovic MP, Shields CH, et al. The Effect of Opioid Dose and Treatment Duration on the Perception of a Painful Standardized Clinical Stimulus. *Reg Anesth Pain Med*. 2008 May 1;33(3):199–206.
63. Tompkins DA, Campbell CM. Opioid-induced hyperalgesia: clinically relevant or extraneous research phenomenon? *Curr Pain Headache Rep*. 2011 Apr;15(2):129–36.
64. Williams T, van Staa T, Puri S, Eaton S. Recent advances in the utility and use of the General Practice Research Database as an example of a UK Primary Care Data resource. *Ther Adv Drug Saf*. 2012 Apr;3(2):89–99.
65. Jones KH, Ford DV, Jones C, Dsilva R, Thompson S, Brooks CJ, et al. A case study of the Secure Anonymous Information Linkage (SAIL) Gateway: A privacy-protecting remote access system for health-related research and evaluation. *Journal of Biomedical Informatics*. Elsevier Inc; 2014 Aug 1;50(C):196–204.
66. All Wales Medicines Strategy Group, National Prescribing Indicators 2019–2020. February 2019. (<http://www.awmsg.org/docs/awmsg/medman/National%20Prescribing%20Indicators%202019-2020.pdf> accessed October 2019)
67. Welsh Government. Living with Persistent Pain in Wales [Internet]. 2019 Apr pp. 1–34. Available from: <https://gov.wales/sites/default/files/publications/2019-05/living-with-persistent-pain-in-wales.pdf>
68. Smith JG, Knight L, Stewart A, Smith EL, McCracken LM. Clinical effectiveness of a residential pain management programme – comparing a large recent sample with previously published outcome data. *British Journal of Pain*. 4 ed. 2016 Jan 21;10(1):46–58.
69. Damush TM, Kroenke K, Bair MJ, Wu J, Tu W, Krebs EE, et al. Pain self-management training increases self-efficacy, self-management behaviours and pain and depression outcomes. *European Journal of Pain*. 4 ed. 2016 Feb 5;20(7):1070–8.
70. Turk DC, Swanson KS, Tunks ER. Psychological approaches in the treatment of chronic pain patients - When pills, scalpels, and needles are not enough. *Can J Psychiatry*. 2008 Apr 1;53(4):213–23.

71. McGrane N, Galvin R, Cusack T, Stokes E. Addition of motivational interventions to exercise and traditional Physiotherapy: A review and meta-analysis. *Physiotherapy*. 2015 Jan 1;101(1):1–12.
72. Dowell D, Haegerich, TM & Chou R, 2016. CDC Guideline for Prescribing Opioids for Chronic Pain--United States, 2016. *JAMA*, 315(15), pp.1624–1645.
73. Harrison H and Cormack J. Quality Prescribing for Chronic Pain. A Guide for Improvement 2018 – 2021. <https://www.therapeutics.scot.nhs.uk/wp-content/uploads/2018/03/Strategy-Chronic-Pain-Quality-Prescribing-for-Chronic-Pain-2018.pdf>
74. Mills S, Torrance N, Smith BH. Identification and Management of Chronic Pain in Primary Care: a Review. *Curr Psychiatry Rep*. 2016 Feb 1;18(2):1–9.
75. Gordon K, Rice H, Allcock N, Bell P, Dunbar M, Gilbert S, et al. Barriers to self-management of chronic pain in primary care: a qualitative focus group study. *Br J Gen Pract*. 2017 Mar;67(656):e209–17.
76. McCrorie C, Closs SJ, House A, Petty D, Ziegler L, Glidewell L, et al. Understanding long-term opioid prescribing for non-cancer pain in primary care: a qualitative study. *BMC Family Practice*. *BMC Family Practice*; 2015 Sep 3;16(1):1–9.
77. Finestone HM, Juurlink DN, Power B, Gomes T, Pimlott N. Opioid prescribing is a surrogate for inadequate pain management resources. *Can Fam Physician*. The College of Family Physicians of Canada; 2016 Jun 1;62(6):465–8.

List of figures

Figure 1: Trends in opioid prescribing across Wales, 2005 - 2015. (A) Annual daily oral morphine equivalent (OMED) in mg per 1000 population, stratified by drug. (B) Number of prescriptions per 1000 population stratified by drug (C) Annual daily OMED (mg) per prescription issued and stratified by drug

Figure 2: Trends in high-dose (>120mg OMED per day) opioid prescribing in Wales, 2005-2015. (A) Daily OMED (mg) per 1000 population stratified by drug (B) OMED (mg) per prescription issued stratified by drug

Figure 3: Trends in opioid prescribing across Wales, 2005 - 2015. (A) Annual daily oral morphine equivalent (OMED) (mg) per 1000 population, stratified by deprivation. (B) Number of prescriptions per 1000 population stratified by deprivation (C) Annual daily OMED (mg) per prescription issued and stratified by deprivation. Welsh Index of Multiple Deprivation 2011 (WIMD2011) where WIMD1=most deprived, WIMD5=least deprived

Figure 4: Trends in high-dose opioid (>120mg OMED) prescribing across Wales, 2005 - 2015. (A) Annual daily oral morphine equivalent (OMED) in mg per 1000 population, stratified by deprivation. (B) OMED (mg) per prescription stratified by deprivation (C) OMED (mg) per person issued a prescription and stratified by deprivation. Welsh Index of Multiple Deprivation 2011 (WIMD2011) where WIMD1=most deprived, WIMD5=least deprived







